Form 4: Lemaitre Vascular Director Accrues Dividend Equivalent Rights

Director John James O'Connor of Lemaitre Vascular Inc. reported the accrual of dividend equivalent rights tied to existing equity awards.

Summary

• John James O'Connor, a Director at LEMAITRE VASCULAR INC (LMAT), reported the acquisition of dividend equivalent rights (DERs) on March 26, 2026.
• These DERs accrued on previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• The DERs vest proportionately with their respective underlying RSU and PSU awards.
• Specific accruals include 0.3941 DERs (total 4.6016 owned) from a 12/8/2023 RSU award, 0.472 DERs (total 4.3113 owned) from a 12/8/2023 PSU award, 0.6426 DERs (total 3.5389 owned) from a 12/6/2024 RSU award, 0.7276 DERs (total 3.6239 owned) from a 12/6/2024 PSU award, and 1.2077 DERs (total 1.2077 owned) from a 12/10/2025 RSU award.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. It represents a routine disclosure of director compensation, which is a standard part of corporate governance and aligns insider interests with shareholders, without indicating any significant operational or financial news.

Positives

• The accrual of dividend equivalent rights increases the director's potential future equity ownership in Lemaitre Vascular, aligning their interests with shareholders.
• This transaction represents a routine component of executive compensation, indicating ongoing participation in the company's equity incentive plans.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into insider ownership and compensation structures. The accrual of dividend equivalent rights is a common mechanism in executive compensation packages, designed to provide executives with the economic benefit of dividends on unvested equity awards, further aligning their incentives with long-term shareholder value creation. This is a standard disclosure for publicly traded companies.

Comparison to Industry Standards

• The use of dividend equivalent rights tied to restricted stock units and performance share units is a common practice in executive compensation across various industries, including the medical device sector where Lemaitre Vascular operates.
• This compensation structure is consistent with typical corporate governance practices aimed at retaining key talent and incentivizing long-term performance, similar to peers in the medical technology space.

Stakeholder Impact

• Shareholders: Increased transparency regarding director compensation and potential for enhanced alignment of director interests with long-term shareholder value.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Next Steps

• The dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards.

Key Dates

Keywords

LEMAITRE VASCULAR, LMAT, Form 4, insider transaction, director compensation, dividend equivalent rights, equity awards, restricted stock units, performance share units